Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis
Authors:
- Machaon BonafedeMBMachaon Bonafede
- George J. JosephGJGeorge J. Joseph
- Nicole PrincicNPNicole Princic
- David J. HarrisonDHDavid J. Harrison
- 9 July 2013
- journal article
- research article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 16 (9) , 1120-1128
Abstract
To estimate annual biologic response modifier (BRM) cost per treated patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, and/or ankylosing spondylitis receiving etanercept, abatacept, adalimumab, certolizumab, golimumab, infliximab, rituximab, or ustekinumab. This was a cohort study of 69,349 commercially insured individuals in a nationwide claims database with one of these conditions that had a claim for one of these BRMs between January 2008 and December 2010 (the index BRM/index date). Cost per treated patient was calculated as the total BRM acquisition and administration cost to the payer in the first year after the index date (including costs of other BRMs after switching) divided by the number of patients who received the index BRM. Etanercept was selected as the reference for comparisons. Etanercept was the most commonly used index BRM (n = 32,298; 47%), followed by adalimumab (n = 20,582; 30%), infliximab (n = 11,157; 16%), abatacept (n = 2633; 4%), rituximab (n = 1359; 2%), golimumab (n = 687; <1%), ustekinumab (n = 388; <1%), and certolizumab (n = 245; <1%). Using etanercept as the reference, the cost per treated patient in the first year across all four conditions was 102% for adalimumab and 108% for infliximab. Newer BRMs had costs relative to etanercept that were 90% to 102% for rheumatoid arthritis, 132% for psoriasis, 100% for psoriatic arthritis, and 94% for ankylosing spondylitis. Potential study limitations were the lack of clinical information (e.g., disease severity, treatment outcomes) or indirect costs, the inability to compare costs of newer BRMs across all four conditions, and much smaller sample sizes for newer BRMs. Of the BRMs that are approved for indications within all four conditions studied, etanercept had the lowest cost per treated patient when assessed across all four conditions.Keywords
This publication has 18 references indexed in Scilit:
- Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveHealth Economics Review, 2012
- Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyCurrent Medical Research and Opinion, 2012
- Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patientsJournal of Medical Economics, 2011
- Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesJournal of Medical Economics, 2011
- Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2011
- Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritisAmerican Journal of Health-System Pharmacy, 2010
- The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritisCurrent Medical Research and Opinion, 2008
- Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims dataCurrent Medical Research and Opinion, 2007
- Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical centerArthritis Care & Research, 2005